Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study
- PMID: 19808353
- PMCID: PMC2993567
- DOI: 10.1161/CIRCHEARTFAILURE.108.828343
Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study
Erratum in
- Circ Heart Fail. 2009 Nov;2(6):e4
Abstract
Background: Myocardial fibrosis reflects excess collagen deposition in the extracellular left ventricular matrix, which has been associated with heart failure (HF). No studies have addressed the relation between fibrosis biomarkers and HF in the elderly.
Methods and results: Serum fibrosis markers were measured in 880 participants of the Cardiovascular Health Study (mean age 77+/-6 years, 48% women). Participants with systolic HF (n=131, left ventricular ejection fraction <55%) and those with diastolic HF (n=179, left ventricular ejection fraction > or =55%) were compared with controls (280 with cardiovascular risk factors, and 279 healthy individuals) using a nested case-control design. Fibrosis markers included carboxyl-terminal peptide of procollagen type I, carboxyl-terminal telopeptide of collagen type I, and amino-terminal peptide of procollagen type III. Echocardiography was used to document systolic and diastolic function parameters. Analysis of variance and logistic regression analysis (per tertile odds ratios [OR]), adjusted by age, gender, race, hypertension, atrial fibrillation, coronary heart disease, baseline serum glucose, serum cystatin C, serum creatinine, C-reactive protein, any angiotensin-converting enzyme inhibitor, spironolactone or any diuretic, NT-proBNP, and total bone mineral density were performed. Systolic HF was associated with significantly elevated carboxyl-terminal telopeptide of collagen type I (OR=2.6; 95% CI=1.2 to 5.7) and amino-terminal peptide of procollagen type III (OR=3.3; 95% CI=1.6 to 5.8), when adjusting for covariates. Associations of diastolic HF were significant for carboxyl-terminal telopeptide of collagen type I (OR=3.9; 95% CI=1.9 to 8.3) and amino-terminal peptide of procollagen type III (OR=2.7; 95% CI=1.4 to 5.4). HF was not associated with elevated carboxyl-terminal peptide of procollagen type I (P>0.10), and fibrosis markers did not significantly differ between HF with diastolic versus those with systolic dysfunction (P>0.10) whereas NT-proBNP mean values were higher in systolic heart failure than in diastolic heart failure (P<0.0001).
Conclusions: Fibrosis markers are significantly elevated in elderly individuals with diastolic or systolic HF. These associations remained significant when adjusting for covariates relevant to the aging process.
Conflict of interest statement
Disclosures:
No conflicts to disclose.
Figures
References
-
- Weber KT, Sun Y, Tyagi SC, Cleutjens JPM. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol. 1994;26:271–292. - PubMed
-
- Brilla CG. The cardiac structure-function relationship and the renin-aldosterone system in hypertension and heart failure. Curr Opin Cardiol. 1994;9:S2–S10. 1. - PubMed
-
- Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI. Collagen remodeling of the pressure- overloaded, hypertrophied nonhuman primate myocardium. Circ Res. 1988;62:757–765. - PubMed
-
- Izawa H, Murohara12345 T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation. 2005;112:2940–2945. - PubMed
Publication types
MeSH terms
Grants and funding
- T32 HL007902/HL/NHLBI NIH HHS/United States
- N01 HC085080/HL/NHLBI NIH HHS/United States
- 1-T32-HL07902/HL/NHLBI NIH HHS/United States
- N01 HC085082/HL/NHLBI NIH HHS/United States
- N01-HC-85081/HC/NHLBI NIH HHS/United States
- R37 AG018915/AG/NIA NIH HHS/United States
- N01-HC-85082/HC/NHLBI NIH HHS/United States
- RC-HL35129/HL/NHLBI NIH HHS/United States
- N01 HC085081/HL/NHLBI NIH HHS/United States
- P50 HL015103/HL/NHLBI NIH HHS/United States
- 1 R03 AG23291/AG/NIA NIH HHS/United States
- N01 HC085086/HL/NHLBI NIH HHS/United States
- N01 HC085083/HL/NHLBI NIH HHS/United States
- AG09556/AG/NIA NIH HHS/United States
- N01 HC085085/HC/NHLBI NIH HHS/United States
- N01-HC-85086/HC/NHLBI NIH HHS/United States
- RC-HL15103/HL/NHLBI NIH HHS/United States
- N01 HC085079/HL/NHLBI NIH HHS/United States
- N01-HC-85083/HC/NHLBI NIH HHS/United States
- N01-HC-85080/HC/NHLBI NIH HHS/United States
- R01 HL043201/HL/NHLBI NIH HHS/United States
- HL43201/HL/NHLBI NIH HHS/United States
- R03 AG023291/AG/NIA NIH HHS/United States
- N01 HC085084/HC/NHLBI NIH HHS/United States
- N01-HC-85079/HC/NHLBI NIH HHS/United States
- R37 AG18915/AG/NIA NIH HHS/United States
- R01 AG009556/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
